Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer
Artikel i vetenskaplig tidskrift, 2015

Background: The aim of this study was to compare the efficacy and hematologic toxicity of cetuximab combined with various types of chemotherapy regimens in patients with KRAS wild-type metastatic colorectal cancer (mCRC). Methods: The response rate, progression-free survival (PFS) and overall survival of the patients were analyzed. Results: In total, 45 patients were included in the study. The overall response rate for the combination of cetuximab and FOLFOX, FOLFIRI and CAPOX was 20, 46 and 30%, respectively, but the differences were not statistically significant. The median PFS for the three groups were 8, 6 and 3.5 months, respectively, but again these differences were not significant. All-grade leukopenia and anemia for the cetuximab plus FOLFOX group were significantly higher than for the other chemotherapy regimens. Conclusion: Our findings suggest that the combination of cetuximab and the three standard chemotherapy regimens resulted in the same outcomes in our patient population of mCRC, with higher hematologic toxicities among the FOLFOX subgroup.

KRAS

Metastatic colorectal cancer

Cetuximab

Chemotherapy

Författare

P. Azadeh

Shahid Beheshti University of Medical Sciences

N. Mortazavi

Shahid Beheshti University of Medical Sciences

A. Tahmasebi

Amirkabir University of Technology

Farnaz Hosseini Kamal

Chalmers, Kemi och kemiteknik

K. Novin

Shahid Beheshti University of Medical Sciences

Chemotherapy

0009-3157 (ISSN) 1421-9794 (eISSN)

Vol. 61 1 51-56

Ämneskategorier

Farmakologi och toxikologi

DOI

10.1159/000440693